Up in arms over ARBs

According to a report in the Wall Street Journal, FDA officials are in a tussle over angiotensin-receptor blockers (ARBs). Based on evidence of an increased risk in cancer, one reviewer argues for a stronger warning but his bosses aren’t convinced. They describe such action as a diversion from assessing new drug applications.